共 49 条
[1]
Tannock IF(2004)Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer N Engl J Med 351 1502-1512
[2]
de Wit R(2004)Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer N Engl J Med 351 1513-1520
[3]
Berry WR(2010)Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial Lancet 376 1147-1154
[4]
Petrylak DP(2013)Abiraterone in metastatic prostate cancer without previous chemotherapy N Engl J Med 368 138-148
[5]
Tangen CM(2011)Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America Clin Infect Dis 52 e56-e93
[6]
Hussain MH(2006)2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline J Clin Oncol 24 3187-3205
[7]
de Bono JS(2011)Myeloid gowth factors J Natl Compr Cancer Netw 9 914-932
[8]
Oudard S(2011)Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study J Clin Oncol 29 3457-3465
[9]
Ozguroglu M(1988)Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan Cancer 61 195-202
[10]
Ryan CJ(2008)Docetaxel plus prednisolone for the treatment of metastatic hormone-refractory prostate cancer: a multicenter Phase II trial in Japan Jpn J Clin Oncol 38 365-372